Comirnaty mRNA Vaccine First To Get EU Clearance For Under-12s
No Impact Expected On Supply Of Vaccine, Say Pfizer & BioNTech
Executive Summary
The EMA is going all out to maximize coverage of the EU population with both vaccines and treatments for COVID-19.
You may also be interested in...
EU Approval In View For Novavax COVID-19 Vaccine; EMA OKs Janssen Booster
It’s all go on the EU coronavirus front this week: three new therapies and another vaccine booster have been recommended for use, and a special session on the Novavax vaccine is to be held at the EMA next week. More production capacity has been OKd for three vaccines.
Pfizer/BioNTech’s Comirnaty Supply Agreements Unaffected Despite EU Green Light For Under-12s
Pfizer and BioNTech’s Comirnaty supply under existing agreements will continue as planned despite anticipated expansion into a new child sub-population in Europe.
Coronavirus Notebook: Molnupiravir EU Approval Likely By Year End, Special CHMP Session Due On Comirnaty in 5 to 11-year-olds
The EMA is assessing the Janssen vaccine as a booster, and Switzerland is evaluating the use of the Pfizer/BioNTech and Moderna COVID-19 vaccines in younger age groups. The WHO has announced the first voluntary global license on a COVID-19 antibody detection technology.